open access

Vol 82, No 6 (2011)
ARTICLES
Get Citation

Evaluation of IL-10 and TGF-beta levels and myeloid and lymphoid dendritic cells in ovarian cancer patients

Rafał Tarkowski, Grzegorz Polak, Iwona Wertel, Maria Kotarska
Ginekol Pol 2011;82(6).

open access

Vol 82, No 6 (2011)
ARTICLES

Abstract

Abstract Aim: The aim of the study was to evaluate IL-10 and TGF-beta levels in the peritoneal fluid (PF) and plasma of patients with ovarian cancer (n=104), serous cyst (n=32) or normal controls (n=20). IL-10 and TGF-beta levels were correlated to myeloid (M) and lymphoid (L) dendritic cells (DC). Material and Methods: IL-10 and TGF-beta concentrations were evaluated using the enzyme linked immunosorbent assay (ELISA). The percentage of DC in mononuclear cells was quantified by using flow cytometry. Results: The PF and plasma IL-10 concentrations were significantly higher in epithelial ovarian cancer (EOC) patients when compared to the women with serous cyst (the reference group). Plasma levels of IL-10 were elevated in EOC patients in comparison with the reference and control groups. There were significant differences in the PF and plasma IL-10 levels with respect to tumor stage, grade and histology. Significant negative correlations were found between the plasma IL-10 levels, MDC and LDC in the peripheral blood. TGF-beta levels were detected in PF of all EOC patients and were significantly lower when compared with plasma. Plasma levels of TGF-beta were elevated in EOC patients compared with the control group. No significant differences in the PF and plasma TGF-beta levels were noted between EOC patients and the reference group. The authors did not find a correlation between the plasma and PF TGF-beta levels and the percentage of MDC and LDC. Conclusions: IL-10 production in EOC patients depends on the tumor stage, grade and histological type of the tumor cells. IL-10 may have impact on the percentage of dendritic cells in EOC patients.

Abstract

Abstract Aim: The aim of the study was to evaluate IL-10 and TGF-beta levels in the peritoneal fluid (PF) and plasma of patients with ovarian cancer (n=104), serous cyst (n=32) or normal controls (n=20). IL-10 and TGF-beta levels were correlated to myeloid (M) and lymphoid (L) dendritic cells (DC). Material and Methods: IL-10 and TGF-beta concentrations were evaluated using the enzyme linked immunosorbent assay (ELISA). The percentage of DC in mononuclear cells was quantified by using flow cytometry. Results: The PF and plasma IL-10 concentrations were significantly higher in epithelial ovarian cancer (EOC) patients when compared to the women with serous cyst (the reference group). Plasma levels of IL-10 were elevated in EOC patients in comparison with the reference and control groups. There were significant differences in the PF and plasma IL-10 levels with respect to tumor stage, grade and histology. Significant negative correlations were found between the plasma IL-10 levels, MDC and LDC in the peripheral blood. TGF-beta levels were detected in PF of all EOC patients and were significantly lower when compared with plasma. Plasma levels of TGF-beta were elevated in EOC patients compared with the control group. No significant differences in the PF and plasma TGF-beta levels were noted between EOC patients and the reference group. The authors did not find a correlation between the plasma and PF TGF-beta levels and the percentage of MDC and LDC. Conclusions: IL-10 production in EOC patients depends on the tumor stage, grade and histological type of the tumor cells. IL-10 may have impact on the percentage of dendritic cells in EOC patients.
Get Citation

Keywords

dentritic cell, ovarian cancer, IL-10, TGF-beta

About this article
Title

Evaluation of IL-10 and TGF-beta levels and myeloid and lymphoid dendritic cells in ovarian cancer patients

Journal

Ginekologia Polska

Issue

Vol 82, No 6 (2011)

Bibliographic record

Ginekol Pol 2011;82(6).

Keywords

dentritic cell
ovarian cancer
IL-10
TGF-beta

Authors

Rafał Tarkowski
Grzegorz Polak
Iwona Wertel
Maria Kotarska

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl